# case_12_node_1 skill analysis

## Outcome

- Prediction: `无明显获益`
- Ground truth: `明显获益`
- Primary binary outcome: incorrect
- Run status: complete, LLM-generated

## Reusable failure pattern

The target regimen was alectinib after intracranial progression on ensartinib. Retrieval did not locate direct early-window evidence for that exact sequence. Evidence Review still recorded four supporting and three contradicting findings, but AnswerContext forwarded zero findings and zero evidence IDs. Generate then treated missing direct evidence and prior-drug progression as grounds for a no-benefit prediction.

The reusable defect is not the drug-specific answer. It is the collapse of three distinct states—positive evidence, negative evidence, and unknown—plus loss of accepted evidence at the AnswerContext boundary.

## Candidate skill

- Skill: `evidence-absence-calibration`
- Stages: Evidence Review, AnswerContext, Generate
- Trigger: no direct evidence; accepted evidence disappears; or progression occurred under a prior intervention
- A/B status: pending
- Required held-out validation: cases outside batch 002 where direct evidence is missing, including both benefit and no-benefit ground truths
